橙子视频app安卓下载,91橙子视频,橙子视频旧款,橙子视频在线官网

SGI-1027 is a potent and selective inhibitor of DNA methyltransferase (DNMT) with IC₅₀ of 6, 8, 7.5 µM for DNMT1, DNMT3A, and DNMT3B. It competes with S-adenosylmethionine in the methylation reaction. Treatment of different cancer cell lines with SGI-1027 resulted in selective degradation of DNMT1 with minimal or no effects on DNMT3A and DNMT3B. SGI-1027 exhibits a moderate pro-apoptotic effect on U937 human leukemia cell line with no relevant changes on the cell cycle. SGI-1027 acts as a novel class of DNA hypomethylating agent that has the potential for use in epigenetic cancer therapy.

How to Use:

• In vitro: SGI-1027 was used at 10-300 µM final concentration in various in vitro assays.
• In vivo: n/a

Reference:

1. 1. Datta J, et al. A new class of quinoline-based DNA hypomethylating agents reactivates tumor suppressor genes by blocking DNA methyltransferase 1 activity and inducing its degradation. (2009) Cancer Res. 69(10):4277-85.
2. 2. García-Domínguez P, et al. Synthetic approaches to DNMT inhibitor SGI-1027 and effects on the U937 leukemia cell line. (2013) Bioorg Med Chem Lett. 23(6):1631-5.
3. 3. Yoo J, et al. Molecular modeling studies of the novel inhibitors of DNA methyltransferases SGI-1027 and CBC12: implications for the mechanism of inhibition of DNMTs. (2013) PLoS One. 8(4):e62152.
4. 4. Gamage SA, et al. Structure-activity relationships for 4-anilinoquinoline derivatives as inhibitors of the DNA methyltransferase enzyme DNMT1. (2013) Bioorg Med Chem. 21(11):3147-53.

Products are for research use only. Not for human use.